Ansun Biopharma, Inc.

NEWS
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 7, 2020.
BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* no earlier than 2017.
Ansun Biopharma closed on a Series A financing round worth $85 million. The company plans to use the funds raised for a Phase III clinical trial of its experimental anti-viral drug, DAS181.
IN THE PRESS
AWARDS
  • NextGen Class of 2019
JOBS